Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Overview

About this study

The purpose of this study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis. People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

-The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria.
-The participant has an EDSS score ≤ 5.5 at the first visit (Screening Visit)
-The participant must have at least 1 of the following prior to screening:

  • ≥ 1 documented relapse within the previous year OR 
  • ≥ 2 documented relapses within the previous 2 years, OR
  • ≥ 1 documented Gd enhancing lesion on an MRI scan within the previous year.

-Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

-The participant has been diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria
-The participant has a history of infection or may be at risk for infection:
-The presence of psychiatric disturbance or substance abuse.
-History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment.
-History or current hypogammaglobulinemia.
-A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis.
-The participant has had a relapse in the 30 days prior to randomization.
-The participant has contraindication for MRI, ie, presence of pacemaker, metallic implants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips), presence of metallic material (eg, shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol scheduled MRI scans. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/27/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Iris Marin Collazo, M.D.

Contact us for the latest status

Contact information:

Pamela Desaro C.C.R.C.

Desaro.Pamela@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20569432

Mayo Clinic Footer